OptiNose presents data on highly effective migraine treatment

June 28, 2008

BOSTON, MA - Saturday June 28, 2008 - OptiNose announced today that it presented important new data demonstrating the superior performance of its novel nasal drug delivery device with sumatriptan for the treatment of migraines. The Phase II results indicate that the drug-device combination achieves migraine relief as quickly and efficiently as injections without the discomfort, inconvenience and risk of needle-stick injuries. OptiNose presented the data at the Annual Scientific Meeting of the American Headache Society in Boston.

Headache relief was achieved in 74.3% and 83.8% of patients at 60 minutes and 120 minutes after administration, respectively, and 48.6% of patients remained pain free after 48 hours. The results were statistically significant when compared to the study's placebo group. The study also confirmed earlier Phase I results. In the Phase I study, the OptiNose powder nasal drug delivery device achieved the maximum sumatriptan concentration in the blood at a median time of 20 minutes after administration. This result was comparable to injections and much faster than other intranasal delivery technologies.

"We are excited to develop this new treatment for the approximately 30 million Americans who suffer from migraines," said Per Djupesland, M.D., Ph.D., the study's co-author and Chief Scientific Officer at OptiNose AS. "Our new device combination will offer patients a much-needed alternative to existing, slower-acting nasal inhalers and tablets and painful injections."

The user feedback from patients who participated in the study was also very encouraging. "The majority of the migraine patients found the device to be both comfortable and easy to use." said Dr Djupesland. "We believe that we can offer a unique therapy for migraine sufferers, combining fast relief, low side effects and high user compliance."

Unlike traditional nasal delivery devices, the unique design of the OptiNose device ensures that drug is delivered to target sites throughout the entire nasal cavity, achieving optimal dose delivery while avoiding the risk of drug deposition to the lungs.
-end-
OptiNose AS

OptiNose AS is a private Norwegian company. OptiNose has developed a series of nasal drug delivery devices for use with a number of topical, systemic and CNS compounds and with applications for both liquid and powder formulations. In addition, OptiNose has developed two drug-device products that have completed Phase II clinical trials. Both the delivery technology and products are available for licensing. Interested parties should contact Helena Djupesland, CEO, at +47 90 885 643 to learn more.

OptiNose

Related Migraines Articles from Brightsurf:

TMS shows promise in treating stroke, dementia and migraines
TMS shows promise in treating a broad range of neurological disorders, including stroke, dementia and migraines.

Nightly sleep disturbance linked to daily risk of migraines
The team's findings generally support patients' reports of sleep disturbance as a trigger for migraines.

A new link between migraines, opioid overuse may be key to treating pain
Researchers have discovered that a peptide links together migraine pain and pain induced by opioid overuse.

Migraines linked to higher risk of dementia
Dementia is the most common neurological disease in older adults, whereas headaches, including migraines, are the most common neurological disorder across all ages.

1-2 caffeinated drinks not linked with higher risk of migraines; 3+ may trigger them
In a study published in the American Journal of Medicine, researchers at Beth Israel Deaconess Medical Center (BIDMC), Brigham and Women's Hospital and the Harvard T.H.

New antibody treatment provides little relief for high-frequency migraine patients
An early assessment reveals that the newly approved antibody treatment Erenumbab does not seem effective among patients who suffer from high-frequency migraines.

Migraine increases the risk of complications during pregnancy and childbirth
Pregnant women with migraine have an increased risk of miscarriage, caesarean sections and giving birth to a child with low birth weight.

Migraines may increase risk of pregnancy complications
In a study of women in Denmark with and without migraines who became pregnant, migraines were associated with an increased risk of pregnancy-associated hypertension disorders in the mother.

One in every 12 Canadian with migraines has attempted suicide
A new study by the University of Toronto, published online this week in the journal Archives of Suicide Research, found that adults with migraine who had been sexually abused during childhood were three times more likely to have attempted suicide.

Discovery of novel mechanisms that cause migraines
Researchers at CNRS, Université Côte d'Azur and Inserm have demonstrated a new mechanism related to the onset of migraine.

Read More: Migraines News and Migraines Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.